TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean score of oral health impact
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean value of caries experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: I-FABP to measure epithelial wall injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: zonulin to measure tight junction leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactic acid to measure fatigue after the race
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cumulative excretion of [14C] Yiqibuvir-related material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral health knowledge and practice questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of missing and decayed teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative measurement of M protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS scores during cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Numerical Pain Scale (NMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fascia stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Sensitivity Scale (PSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) & Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate Per Immune Response Evaluation Criteria in Solid Tumors (iRECIST) (iORR) by Independent Central Review
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of postoperative analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence Prediction Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Size of wart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemiluminescent Immunoassay for Human Immunodeficiency Virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Carcinoembryonic Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Alpha Fetoprotein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Carbohydrate Antigen 19-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mucin-16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of subjects with at least one treatment-related adverse event (AE) or serious adverse event (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with abnormal heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with abnormal respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with abnormal systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with abnormal oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC0_t of DWP16001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child prevalence of soil-transmitted helminth infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Retention Percentage of Youth/Young Adults in YE Prevention Programming
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of subjects achieving PASI 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: sPGA of 0 or 1 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence of Dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response (OR) defined as best overall response (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HF treatment adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Depression, Anxiety, and Stress scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in Professional Satisfaction index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in Insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: 24-hour urinary protein quantitation (24h UTP) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: macular vascular density or foveal avascular zone area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: 6-month radiographic progression-free survival (rPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Next-generation sequencing analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Texture and Radiance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recurrent Prosthetic Joint Infection (PJI)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Adverse event assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Change of VO2 max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-hepatic progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility using eligibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility using the proportion of consent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in musculoskeletal pain symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of patients with plasma HIV-1 RNA ≥50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Desire for a child
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Biological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t): Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax): Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Systemic Clearance (CL/F): Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awareness score of driving ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Driving performance variables measured by the driving simulator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative echocardiographic mitral valve repair success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Viral Clearance During the Follow up Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Graft Loss in Six-month Follow up Period
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients successfully staying off medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Antibody Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of anastomotic leakage diagnosed by CT-scan or reoperation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recurrence after colorectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Change in lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Two-point discrimination threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum hand grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Responder Status Based on Disease Activity Score 28 Joints (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Responder Status Based on Eczema Area and Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Responder Status Based on Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving the Responder status Based on Active Joint Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CMV syndrome or disease
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants Tested for COVID-19
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Seroprevalence of antibodies to Clostridioides difficile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-S neutralizing antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of breast abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Pain/Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebrovascular reactivity using transcranial Doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cerebrovascular reactivity using functional near infrared spectroscopy (fNIRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the total AQLQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prolonged Grief Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: WHO-5 well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hematology and Clinical Chemistry analyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications onset
Endpoint domain: Adverse events/effects
Primary endpoint: MRI scans of the stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean fatigue score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Overall comfort averaged over all scheduled follow-up visits
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vision averaged over all scheduled follow-up visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The proportion of eyes with a maximum degree of front surface deposits grade of < 2 over all scheduled follow-up visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The proportion of eyes with any slit-lamp findings greater than Grade 2 over all follow-up visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experience Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with continued NCSE on EEG after 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Oral microbiome composition changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hopkins Symptom Checklist Short Form (HSCL-11)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the number of headache days of moderate to severe intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor necrosis factor alpha (TNFa) production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T-cell infiltration as percent of total cell infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fold induction in genes related to wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number/Percentage of Participants with Treatment-Emergent Adverse Events Leading to Permanent Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number/Percentage of Participants with Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Homeostatic Sleep Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sleep Onset Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in REM Sleep Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Overall Sleep Health
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in patient confidence in self-management activities
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in heart failure self-care behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants recruited and risk stratified
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Boston Carpal Tunnel Questionnaire - Symptom Severity Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Boston Carpal Tunnel Questionnaire - Functional Status Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Alleviation of subthreshold depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: frequency and severity of adverse cognitive outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fugl-Meyer Assessment of Upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Modified OSWESTRY Low Back pain Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: effective tumor dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: safe healthy liver dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the Eversense 524 CGM System and ROME CGM System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the Eversense 524 CGM System and ROME CGM System
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Antenatal Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in Perceived Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant Satisfaction with the Modified Mindfulness Training Program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Normalized percentage of achieving the highest possible score for blood pressure measurement technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Normalized percentage of achieving the highest possible score for documentation of delivery of patient education on hypertension
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Fish Skin Graft Device Related failure
Endpoint domain: Adverse events/effects
Primary endpoint: Fish Skin Graft Device related allergy
Endpoint domain: Adverse events/effects
Primary endpoint: Target Wound Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Interleukin 6 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: functional reach test (FRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermal sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laxity of ligament
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Nonattachment Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Rates of Muscle Protein Synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean speed of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-BEStest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip strength dynamometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in red blood cell 2,3-biphosphoglycerate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of restless leg syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Health-related quality of life [HRQoL]
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total number of negative acts children have been exposed to by peers
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Total number of negative acts children have exposed peers to
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Percentage of participants free of TMA manifestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of CPR time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skin hydration from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in skin radiance from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in skin elasticity from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in skin thickness from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ankle muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with CTCs (>0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Immunogenicity of the HPV vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximal inspiratory and expiratory pressures (MIP, MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Assessment of seniors᾽ quality of life: WHOQOL-OLD questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of evaluable patients enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient Health Questionnaire-15 (PHQ-15)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Analogue Scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean intensity within functional connectivity map of intrinsic network
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Highest tolerated dose of peanut protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to prehabilitation components
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progression free survival (PFS) rate at 9 months
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of drug-related adverse events (AEs) ≥ CTCAE Grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Inhibitory Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: General Executive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Immune Cell Phenotype and Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The Behavioral Pain Scale (BPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days at home over 30 days
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Days that patients are expired
Endpoint domain: Mortality/survival
Primary endpoint: One Leg Stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetic Neuropathy Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in Child-Pugh score by 2 or more points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: monitoring recurrence
Endpoint domain: Mortality/survival
Primary endpoint: evaluating prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude and pattern of fMRI cortical responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes